[go: up one dir, main page]

AU5698094A - Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role - Google Patents

Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role

Info

Publication number
AU5698094A
AU5698094A AU56980/94A AU5698094A AU5698094A AU 5698094 A AU5698094 A AU 5698094A AU 56980/94 A AU56980/94 A AU 56980/94A AU 5698094 A AU5698094 A AU 5698094A AU 5698094 A AU5698094 A AU 5698094A
Authority
AU
Australia
Prior art keywords
pdgf
bfgf
diseases
plays
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU56980/94A
Inventor
Wolfgang Brysch
Georg Ferdinand Schlingensiepen
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Original Assignee
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH filed Critical Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Publication of AU5698094A publication Critical patent/AU5698094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU56980/94A 1993-12-09 1993-12-09 Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role Abandoned AU5698094A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1993/003461 WO1995016032A1 (en) 1993-12-09 1993-12-09 ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE

Publications (1)

Publication Number Publication Date
AU5698094A true AU5698094A (en) 1995-06-27

Family

ID=8165802

Family Applications (1)

Application Number Title Priority Date Filing Date
AU56980/94A Abandoned AU5698094A (en) 1993-12-09 1993-12-09 Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role

Country Status (2)

Country Link
AU (1) AU5698094A (en)
WO (1) WO1995016032A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997044046A1 (en) * 1996-05-17 1997-11-27 Otsuka Pharmaceutical Co., Ltd. Platelet-derived growth factor expression inhibitor
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JPWO2005087269A1 (en) * 2004-03-16 2008-01-24 株式会社ディナベック研究所 Method for inhibiting tumor growth
WO2009040069A2 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of bq-610 alone or in combination with helodermin as a therapeutic agent
CA2699065A1 (en) * 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
HK1223319A1 (en) 2013-07-12 2017-07-28 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing

Also Published As

Publication number Publication date
WO1995016032A1 (en) 1995-06-15

Similar Documents

Publication Publication Date Title
AU6953896A (en) Inverted chimeric and hybrid oligonucleotides
AU5931290A (en) Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
EP0789592A4 (en) Ocular gene therapy
ZA963434B (en) Gene therapy using replication competent targeted adenoviral vectors.
ZA968850B (en) Phenylacetic acid derivatives, processes and intermediate for their preparation, and compositions comprising them.
AU7019494A (en) Genetic therapy for cardiovascular disease
AU1238895A (en) The use of benzazoles as UV absorbers, new benzazoles and a process for their preparation
NZ241311A (en) Rna sequence having trans-splicing activity, plant strains
PH31626A (en) Aqueous risperidone formulations.
AU4180593A (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
AU1808595A (en) 3,8-diazabicyclo{3.2.1}octane derivatives having analgesic activity
CA2153254A1 (en) Cloning of enterokinase and method of use
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
EP0309293A3 (en) Method for controlling the front wheel steer angle
EP0654534A3 (en) Processes for producing optically active 2-amino-1-phenylethanol derivatives.
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
EP1131332A4 (en) ANTISENSE MODULATION OF KAPPA B KINASE BETA INHIBITOR EXPRESSION
EP0287091A3 (en) Aqueous coating, its preparation process and its use in the coating by electrophoresis
AU3133889A (en) Method for the treatment of the extraphyramidal side effects associated with neuroleptic therapy
AU5698094A (en) Antisense nucleic acid for the treatment of diseases in which expression of bfgf, pdgf-a or pdgf-b plays a pathogenic role
AU2458988A (en) The preparation, by genetic manipulation, of anticoagulative protein pp4
AU4425397A (en) Antisense gene therapy for rna viruses
EP0617041A3 (en) Cyclic phosphorous acid esters, process for their preparation and their use.
GB2179858B (en) Compositions for treating viral skin diseases.
AU1867297A (en) Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders